KBY Biotech Indexv0.0.34
Search
← Pipeline|QUA-617

QUA-617

Phase 1
By Quanta Ther
Source: Trial-derived·Trials: 2
Modality
Gene Editing
MOA
EGFRi
Target
SMN2
Pathway
DDR
ACCSMA
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Feb 2028
Phase 1Current
NCT06862610
2,791 pts·SMA
2025-07→2028-02·Terminated
NCT03553872
1,632 pts·ACC
2020-10→2026-04·Completed
4,423 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-152w awayInterim· ACC
2028-02-171.9y awayInterim· SMA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Complet…
P1
Termina…
Catalysts
Interim
2026-04-15 · 2w away
ACC
Interim
2028-02-17 · 1.9y away
SMA
CompletedTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT06862610Phase 1SMATerminated2791HAM-D
NCT03553872Phase 1ACCCompleted1632LiverFat
Competitors (10)
DrugCompanyPhaseTargetMOA
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
JNJ-5094Johnson & JohnsonPhase 2/3GIP-REGFRi
NVO-6275Novo NordiskPhase 1SMN2BTKi
GSK-2051GSKPhase 1PSMAEGFRi
TAK-5300TakedaPhase 1SMN2AuroraAi
GIL-8529Gilead SciencesPhase 1/2JAK1EGFRi
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
REG-647RegeneronPreclinicalSMN2SOS1i
207-2754Samsung BiologicsPhase 1/2KRASG12DEGFRi
MavuratamabBlueprint MedicinesNDA/BLABETEGFRi